The "Neurological" Horizon: How 2026 is Using "Hot" Molecules to Treat Alzheimer's.
In late 2026, the industry is pivoting toward "Neuro-Theranostics." While oncology remains the anchor, a radical new class of "Amyloid-Clearing Radiopharmaceuticals" has entered Phase 2 trials, aiming to use targeted radiation to break down the plaques associated with Alzheimer's disease. This innovation is a primary driver for the market, as it promises to treat the brain with...
0 Commenti 0 condivisioni 15 Views 0 Anteprima